Form 4: Collegium Pharma Exec Sells Shares Via 10b5-1 Plan

Collegium Pharmaceutical's EVP & Chief Commercial Officer, Scott Dreyer, sold nearly 50,000 shares of common stock through a pre-arranged trading plan.

Summary

• Scott Dreyer, Executive Vice President & Chief Commercial Officer of Collegium Pharmaceutical, Inc. (COLL), reported transactions involving the sale of common stock.
• On March 3, 2026, Dreyer sold 46,417 shares of common stock at a weighted average price of $40.3636 per share. The sales occurred in multiple transactions ranging from $39.835 to $40.82.
• On the same date, March 3, 2026, an additional 3,559 shares of common stock were sold at a weighted average price of $40.9889 per share. These sales ranged from $40.84 to $41.35.
• Following these transactions, Dreyer beneficially owns 71,770 shares of Collegium Pharmaceutical common stock.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Scott Dreyer on September 3, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale of shares by an executive, while a reduction in their direct holdings, was conducted under a pre-arranged 10b5-1 plan, which mitigates any negative signaling typically associated with insider selling.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 trading plan are a common practice for executives to diversify their holdings and manage personal finances. Such pre-scheduled sales typically do not reflect a change in the executive's view of the company's prospects, unlike open-market sales without a plan, which can sometimes signal a lack of confidence.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be perceived as a minor negative, but the pre-planned nature under Rule 10b5-1 generally reduces concerns about management's confidence in the company's future.

Key Dates

Recommendation

The Form 4 filing details a pre-scheduled insider sale under a Rule 10b5-1 plan, which typically indicates personal financial planning rather than a change in the executive's outlook on the company. Without additional information, this transaction alone does not warrant a change in investment recommendation.

Keywords

Collegium Pharmaceutical, COLL, Insider Trading, Form 4, Stock Sale, Scott Dreyer, 10b5-1 Plan, Executive Compensation